Document Detail

Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
MedLine Citation:
PMID:  11332283     Owner:  NLM     Status:  MEDLINE    
Forty-six, newly detected, previously untreated multibacillary (MB) patients with a bacterial index (BI) of > or = 3+ who had received WHO/MDT for 2 years were followed up for a total duration of 424 person-years and a mean duration of 9.26 +/- 2.98 years per patient. The BIs of the patients continued to fall, and all of the patients, except one, reached skin-smear negativity. WHO/MDT was well accepted and well tolerated. Relapse, which was defined as an increase in the BI of 1+ or more with or without clinical evidence of activity, was observed in only one patient, giving a relapse rate of 2.2% or 0.23 per 100 person-years in patients with a BI of > or = 3+ after long-term follow up. This patient was started on a second course of WHO/MDT to which he responded favorably. WHO/MDT for a fixed duration of 2 years for MB patients as recommended by the WHO is vindicated.
I N Shaw; M M Natrajan; G S Rao; K Jesudasan; M Christian; M Kavitha
Related Documents :
21169873 - Features of large cell transformation of indolent lymphomas as observed on sequential p...
10431403 - Water as an irrigant in transurethral resection of the prostate: a cost-effective alter...
24530753 - Elevated serum levels of lysophosphatidic acid in patients with multiple sclerosis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association     Volume:  68     ISSN:  0148-916X     ISO Abbreviation:  Int. J. Lepr. Other Mycobact. Dis.     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2001-05-02     Completed Date:  2001-05-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8505819     Medline TA:  Int J Lepr Other Mycobact Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  405-9     Citation Subset:  IM    
Department of Community Health, Schieffelin Leprosy Research and Training Center, Karigiri, Vellore District, Tamil Nadu 632 106, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clofazimine / therapeutic use
Cohort Studies
Dapsone / therapeutic use
Drug Therapy, Combination
Follow-Up Studies
Leprostatic Agents / adverse effects,  therapeutic use*
Leprosy / drug therapy*
Neuritis / chemically induced
Rifampin / therapeutic use
World Health Organization
Reg. No./Substance:
0/Leprostatic Agents; 13292-46-1/Rifampin; 2030-63-9/Clofazimine; 80-08-0/Dapsone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Red swamp crawfish (Procambarus clarkii): an alternative experimental host in the study of white spo...
Next Document:  Frequency and extent of thickening of the nucleated epidermis in leprosy lesions.